Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 368.24M P/E - EPS this Y -31.20% Ern Qtrly Grth -
Income -54.39M Forward P/E -8.12 EPS next Y 20.70% 50D Avg Chg 19.00%
Sales 44.39M PEG - EPS past 5Y - 200D Avg Chg 35.00%
Dividend N/A Price/Book 4.10 EPS next 5Y - 52W High Chg -11.00%
Recommedations 2.30 Quick Ratio 8.66 Shares Outstanding 21.79M 52W Low Chg 171.00%
Insider Own 4.90% ROA -32.82% Shares Float 11.80M Beta 1.22
Inst Own 75.92% ROE -74.91% Shares Shorted/Prior 2.02M/2.32M Price 17.78
Gross Margin 84.40% Profit Margin -122.52% Avg. Volume 165,445 Target Price 13.80
Oper. Margin -118.35% Earnings Date Oct 24 Volume 78,251 Change -3.74%
About CVRx, Inc.

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CVRx, Inc. News
11/20/24 CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
11/04/24 CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025
11/01/24 CVRx, Inc. (NASDAQ:CVRX) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
10/30/24 CVRx Inc (CVRX) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses
10/29/24 CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates
10/29/24 CVRx: Q3 Earnings Snapshot
10/29/24 CVRx Reports Third Quarter 2024 Financial and Operating Results
07:42 AM CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock?
05:40 AM CVRx announces new CPT Category I codes for Barostim heart failure therapy
10/19/24 CVRx announces new CPT Category I codes for Barostim
10/15/24 CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024
09/16/24 CVRX Stock Gains on Unveiling of Barostim's Positive Study Data
09/12/24 CVRx touts positive two-year data for heart failure neuromodulation device
09/12/24 CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim
09/03/24 CVRx Announces Appointment of Two New Board Members
08/07/24 Insider Buying: CVRx President Bought US$251k Of Shares
08/05/24 Insider Buying Alert: President & CEO Kevin Hykes Acquires 30,000 Shares of CVRx Inc (CVRX)
08/02/24 CVRx Announces Increased Inpatient Payment for Barostim Procedure
07/31/24 CVRx to Present at the Canaccord Genuity 44th Annual Growth Conference
07/31/24 Analysts Have Made A Financial Statement On CVRx, Inc.'s (NASDAQ:CVRX) Second-Quarter Report
CVRX Chatroom

User Image commoncentsinvestor Posted - 3 hours ago

$CVRX CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference https://ir.cvrx.com/news-releases/news-release-details/cvrx-present-piper-sandler-36th-annual-healthcare-conference

User Image TJmaximus Posted - 1 day ago

$CVRX working the meetings in the halls...

User Image TJmaximus Posted - 1 day ago

$CVRX double congrats? the first time was on the 11th: https://x.com/CVRx_Inc/status/1858985955199512788

User Image 1111tu Posted - 1 day ago

$CVRX Slide from today’s MedAxiom presentation reporting 57% reduction in re-hospitalization for patients receiving Barostim at Prisma.

User Image Phoenix_Sa Posted - 1 day ago

MYNZ Who’s behind the 30M share offering deal? 👀 Thermo Fisher (TMO) partnership ($210B market cap) + PR buzz incoming. $CVRX $BWEN $ARRY

User Image commoncentsinvestor Posted - 1 day ago

$CVRX Join us tomorrow to learn more about how Barostim, a novel device therapy that works with GDMT and targets the neurohormonal pathways responsible for HF progression & symptoms, can help your heart failure patients! https://x.com/MedAxiom/status/1858610455746314332/photo/1

User Image commoncentsinvestor Posted - 1 day ago

$CVRX Congratulations to course Directors, Mark Belkin, MD and Jonathan Grinstein, MD for a wonderful and successful kickoff of the 1st Annual Chicago Hemodynamic Symposium held November 15. This inaugural conference, sponsored by the University of Chicago Heart and Vascular Center, had a packed room and was a deep dive on hemodynamic content. We look forward to watching this program grow. An added thank you to Dr Sean Pinney for his overview of #Barostim. https://x.com/CVRx_Inc/status/1858570535644299362

User Image MITornado Posted - 1 week ago

$CVRX oof… scorched earth out there. wtf?

User Image Fasak Posted - 1 week ago

$CVRX Enjoy the MMs show 🥂

User Image TJmaximus Posted - 1 week ago

$CVRX 4x sales is where I start to look to get back in...

User Image TJmaximus Posted - 1 week ago

$CVRX wash rinse repeat...

User Image Fasak Posted - 1 week ago

$CVRX Short call easy $9 🥂

User Image newfguy Posted - 1 week ago

$CVRX share price over extended and rolling over. price/sales 7.7

User Image commoncentsinvestor Posted - 1 week ago

$CVRX Sacramento, Calif. (November 11, 2024) – Dignity Health Mercy General Hospital, known for cardiac excellence, announced the hospital’s first successful implant of Barostim™ Baroreflex Activation Therapy, the world’s first FDA- approved heart failure device to use neuromodulation – the power of the brain and nervous system – to improve the symptoms of patients with systolic heart failure. This therapy was designed to treat heart failure patients who may not be receiving adequate symptom relief from medications alone. https://www.dignityhealth.org/sacramento/about-us/press-center/mercy-general-hospital-is-first-to-implant-neuromodulation-devic

User Image commoncentsinvestor Posted - 1 week ago

$CVRX FOR NEWCOMERS.....Everything needed to know about Barostim and its benefits. https://video.search.yahoo.com/search/video?fr=uh3_news_web&_tsrc=uh3_news_web&p=barostim#id=4&vid=f320470e417dc881ab6b137e4d937256&action=view

User Image commoncentsinvestor Posted - 1 week ago

$CVRX "Patrick McCann, Heart Failure Director at the #PrismaHealth Advanced Heart Health Center, sees many patients undergoing heart failure who- are able to live longer thanks to current advances in technology, but who still suffer from a reduced quality of life. In this short video, he speaks about new technology that offers a ray of hope: the Barostim device, neuromodulation therapy that helps to reduce symptoms of heart failure and improve overall quality of life. Dr. McCann noted that implantation of the Barostim device is an outpatient procedure that takes around half an hour to complete, requires only small incisions and no part of the device implanation involves surgery on the heart itself. The Barostim device lets people living with heart failure get back to not just surviving, but thriving in the life they love."

User Image commoncentsinvestor Posted - 1 week ago

$CVRX We recently wrapped our final national medical education program of 2024. Thanks to our esteemed faculty and all the physicians, nurses, and advanced practice providers who attended one of our programs this year to learn more about #Barostim, a novel device therapy targeting the neurohormonal pathways in #heartfailure patients. Speak to your Barostim representative if you would like to learn more about our medical education programs and webinars. Drs. Georges Chahoud, Laurie Letarte, @dkenigsberg , @AlbertHicksMD , Manuel Perez, @PanjrathG , Rizwan Alimohammad, Christina Economides, Patrick McCann, Akil Loli, Sam Baradarian, @DrHeartbeats , @RajeevCMohan , Khaled Khalaf, Amarinder Bindra https://x.com/CVRx_Inc/status/1854966424839897212

User Image TJmaximus Posted - 1 week ago

$CVRX looking to trim some

User Image commoncentsinvestor Posted - 1 week ago

$CVRX Dr. Savitri Fedson shares her patient's real-world experience with #Barostim. See how it's improving quality of life for patients, like Johnny, with #heartfailure. https://x.com/CVRx_Inc/status/1854655030705496294

User Image TJmaximus Posted - 1 week ago

$CVRX $CLPT roughly the same market caps but Barostim is better than the smart frame...

User Image commoncentsinvestor Posted - 1 week ago

$CVRX Precedence Research "The global implantable medical devices market size is calculated at USD 113.4 billion in 2024 and is expected to be worth around USD 207 billion by 2033, expanding at a solid CAGR of 6.9% from 2024 to 2033."

User Image GSHSRWD Posted - 1 week ago

$CVRX and he’s back

User Image Fasak Posted - 1 week ago

$CVRX Its hedge funds time as they make money by Shorting stocks! GL bulls!

User Image TJmaximus Posted - 2 weeks ago

$CVRX https://seekingalpha.com/article/4733995-cvrx-stock-impressive-top-line-growth-seems-priced-in

User Image commoncentsinvestor Posted - 2 weeks ago

$CVRX Continue to believe CVRX is grossly undervalued. Here's why. The average Gross Margin in the Medical Device market is 12.1%. CVRX is reporting GM's of 85%. That is 7 times higher than the average. The average Price to Sales ratio in the industry is 4.09. Based upon those averages, CVRX P/S ratio should be should be 28.63. Of course that would be crazy, but a P/S ratio of 10 sure seems more than justified. Looking at Revenues, the company had 178 implant centers going into 2024 and is going to do about $51M in Revenues. That's an average of $286.150 per center. Going into 2025 they will have about 233 Implant Centers. Keeping a similiar average per center would produce 2025 Revenues of $66.7M. Applying a 10 times ratio would produce a Market Cap of $667M. The current MC is $374M.

User Image TJmaximus Posted - 2 weeks ago

$CVRX trimmed a few.

User Image commoncentsinvestor Posted - 2 weeks ago

$CVRX Congratulations to the team at PIH Health Good Samaritan Hospital for achieving a significant milestone - 50 #Barostim implants! We celebrate your commitment to providing innovative therapy options to help improve the lives of #heartfailure patients. #CardioTwitter #cardiology https://x.com/CVRx_Inc/status/1854306177141657785

User Image TJmaximus Posted - 2 weeks ago

$CVRX https://seekingalpha.com/article/4733995-cvrx-stock-impressive-top-line-growth-seems-priced-in

User Image sai1000 Posted - 2 weeks ago

$CVRX why does this continue to just sit here mid $15's?

User Image sai1000 Posted - 2 weeks ago

$DJT recover your losses afterhours at $CVRX

Analyst Ratings
Cantor Fitzgerald Overweight Sep 10, 24
Lake Street Buy Aug 26, 24
Piper Sandler Overweight Jul 30, 24
Canaccord Genuity Buy Jul 30, 24
Craig-Hallum Buy Jul 11, 24
Lake Street Buy Jul 11, 24
Lake Street Buy May 1, 24
Canaccord Genuity Buy May 1, 24
William Blair Market Perform May 1, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
SLATTERY JOSEPH P Director Director Dec 28 Option 1.4 1,950 2,730 22,145 01/02/24
Behbahani Ali Director Director Dec 14 Option 0.237 316 75 316 12/18/23
Galle Liz VP OF GLOBAL CLINICA.. VP OF GLOBAL CLINICAL RESEARCH Oct 16 Option 0.237 778 184 778 10/18/23
VERRASTRO PAUL CHIEF MKTG & STRAT O.. CHIEF MKTG & STRAT OFFICER Aug 03 Sell 18.5549 628 11,652 08/07/23
VERRASTRO PAUL CHIEF MKTG & STRAT O.. CHIEF MKTG & STRAT OFFICER Jul 31 Sell 17.49 1,122 19,624 2,628 08/02/23
VERRASTRO PAUL CHIEF MKTG & STRAT O.. CHIEF MKTG & STRAT OFFICER Jul 31 Option 5.14 3,750 19,275 3,750 08/02/23
Palmer Craig E. SVP, U.S. SALES SVP, U.S. SALES May 16 Option 0.237 295 70 295 05/18/23
VERRASTRO PAUL CHIEF MKTG & STRAT O.. CHIEF MKTG & STRAT OFFICER Nov 28 Sell 12.19 4,600 56,074 4,400 11/30/22
VERRASTRO PAUL CHIEF MKTG & STRAT O.. CHIEF MKTG & STRAT OFFICER Nov 28 Option 5.14 9,000 46,260 9,000 11/30/22
OASHEIM JARED CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Jun 02 Option 0.24 9,585 2,300 9,585 06/06/22
Nielsen Kirk G. Director Director May 24 Buy 5.0498 8,070 40,752 1,711,355 05/26/22
Nielsen Kirk G. Director Director May 19 Buy 5.04 28,795 145,127 1,703,285 05/23/22
Nielsen Kirk G. Director Director Apr 28 Buy 5.97 42,088 251,265 1,612,186 05/02/22
Nielsen Kirk G. Director Director Feb 18 Buy 7.97 104,867 835,790 1,566,698 02/23/22
BRUHN-DING DEAN VP of Reg. Affairs a.. VP of Reg. Affairs and QA Feb 08 Option 0.24 35,000 8,400 54,648 02/10/22
SLATTERY JOSEPH P Director Director Jan 13 Option 0.32 11,640 3,725 20,195 01/18/22
Jain Mudit K. Director Director Nov 18 Buy 14.16 1,175 16,638 2,800 11/19/21